Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia

Eur J Haematol. 2016 Sep;97(3):239-44. doi: 10.1111/ejh.12711. Epub 2015 Dec 28.

Abstract

Objectives: Leukaemia initiating cells reside within specialised niches in the bone marrow where they undergo complex interactions with different stromal cell types. The bone marrow niche is characterised by a low oxygen content resulting in high expression of hypoxia-inducible factor 1 α in leukaemic cells conferring a negative prognosis to patients with acute myeloid leukaemia (AML).

Methods and results: In the current study, we investigated the impact of hypoxic vs. normoxic conditions on the sensitivity of AML cell lines and primary AML blasts to cytarabine. AML cells cultured under 6% oxygen were significantly more resistant against cytarabine compared to cells cultured under normoxic conditions in proliferation and colony-formation assays. Interestingly upon cultivation under hypoxia, the expression of the cytarabine-activating enzyme deoxycytidine kinase was downregulated in all analysed AML cell lines and primary AML samples representing a possible mechanism for resistance to chemotherapy. Furthermore, the downregulation of deoxycytidine kinase could be associated with hypoxia-inducible factor 1 α as treatment with its inhibitor BAY87-2243 hampered the downregulation of deoxycytidine kinase expression under hypoxic conditions.

Conclusions: In conclusion, our data reveal that hypoxia-induced downregulation of deoxycytidine kinase represents one stroma-cell-independent mechanism of drug resistance to cytarabine in acute myeloid leukaemia.

Keywords: Acute myeloid leukaemia; deoxycytidine kinase; drug resistance; hypoxia; hypoxia-inducible factor 1 alpha.

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cytarabine / pharmacology
  • Cytarabine / therapeutic use*
  • Deoxycytidine Kinase / genetics
  • Deoxycytidine Kinase / metabolism*
  • Down-Regulation
  • Drug Resistance, Neoplasm*
  • Gene Expression
  • Humans
  • Hypoxia / metabolism*
  • Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / metabolism*
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism

Substances

  • Antimetabolites, Antineoplastic
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Cytarabine
  • Deoxycytidine Kinase